Navigation auf


Center for Molecular Cardiology

Apelin - a potential therapy for COVID-19?


Seyed Soheil Saeedi Saravi and Jürg H. Beer published a review article about Apelin, a novel agent that might exert beneficial effects on the cardiovasculature in patients having SARS-CoV-2 associated complications, such as lung-injury and coagulopathies, possibly through compromised angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production. They conclude that Apelin might improve Ang-II-mediated inflammation, thrombosis, and vasoconstriction in SARS-CoV-2 positive individuals and that this agent and its receptor agonists could represent a promising molecule to be trialed in COVID-19 patients.